Phathom Pharmaceuticals, Inc. Reports Second Quarter 2026 Financial Results
Key Highlights from the Q2 2026 Report
- Quarter Ended: June 30, 2026
- Common Shares Outstanding: 80,900,934 as of July 27, 2026
- Stock Exchange: Nasdaq Global Select Market (Symbol: PHAT)
- Company Classification: Smaller reporting company; not an emerging growth company; not a shell company
Condensed Balance Sheet (Unaudited, in thousands)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Total Assets | \$327,075 | \$259,149 |
| Current Assets | \$295,915 | \$228,972 |
| Receivables | \$97,422 | N/A |
| Property, Plant & Equipment (Net) | \$971 | N/A |
| Restricted Cash | \$2,864 | \$2,861 |
| Other Long-Term Assets | \$3,088 | N/A |
| Total Liabilities & Stockholders’ Deficit | \$327,075 | \$259,149 |
Liabilities Breakdown (in thousands)
- Accounts Payable: \$5,361 (Q2 2026), \$4,983 (FY 2025)
- Accrued Interest: \$1,436 (Q2 2026)
- Current Portion of Revenue Interest Financing Liability: Not fully detailed, but present
- Long-Term Debt, Net of Discount: \$164,587 (Q2 2026), \$209,087 (FY 2025)
- Revenue Interest Financing Liability (Noncurrent): \$1,855 (Q2 2026)
Stockholders’ Deficit
- Preferred Stock (Authorized): 40,000,000 shares, \$0.0001 par value; Issued and Outstanding: none
- Common Stock (Authorized): 400,000,000 shares, \$0.0001 par value
- Common Stock (Issued & Outstanding): 80,070,048 (Q2 2026), 71,419,025 (FY 2025)
- Treasury Stock: 19 shares at both dates, no value
- Additional Paid-in Capital: \$1,187,928 (Q2 2026), \$1,046,083 (FY 2025)
- Accumulated Deficit: (\$1,532,209) (Q2 2026), (\$1,484,258) (FY 2025)
- Total Stockholders’ Deficit: (\$344,273) (Q2 2026), (\$438,169) (FY 2025)
Key Shareholder Information & Potential Price-Sensitive Items
- Large Net Losses Continue: The company continues to operate with a significant accumulated deficit, which increased to (\$1.53 billion) as of June 30, 2026. This continued negative equity could impact future capital raising efforts and market perception.
- Increase in Shares Outstanding: The number of common shares outstanding increased from 71.4 million to over 80.9 million, a significant dilution over the past six months. This could have a direct impact on per-share values and may be price sensitive for existing shareholders.
- Debt Levels Remain High: The company has substantial long-term debt (over \$164 million) and revenue interest financing liabilities, highlighting ongoing capital needs and potential liquidity challenges.
- Cash Position: The company maintains a healthy cash and current asset balance (\$295.9 million in current assets as of June 2026), which may be reassuring to some investors, but must be viewed in the context of ongoing losses and high debt.
- No Preferred Stock Issued: All preferred stock remains unissued, which means there is current flexibility for future financing but also the potential for further dilution if used.
Regulatory and Compliance Status
- The company has filed all required SEC reports and is up to date on compliance with Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Classified as a “smaller reporting company” and not as an “emerging growth company” or “shell company.”
Potential Share Price Impact
The following items may be particularly price sensitive:
- Share Dilution: The substantial increase in common shares outstanding (over 9 million new shares in the last six months) is likely to be closely watched by investors for its impact on earnings per share and overall dilution.
- Accumulated Deficit: The growing negative stockholders’ equity position signals that the company remains in a development or investment phase, relying on cash reserves and financing rather than profits. This could pressure the share price if investors grow concerned about long-term viability or additional dilution.
- Debt Load: High levels of long-term debt and interest obligations may limit financial flexibility and could be seen as a risk factor by the market.
Conclusion
Phathom Pharmaceuticals, Inc. continues to maintain a strong cash position but faces risks from ongoing losses, a growing deficit, high debt levels, and significant dilution. Investors should closely monitor future financing activities and the company’s ability to move towards profitability.
Disclaimer: This article is a summary and analysis of selected information from Phathom Pharmaceuticals, Inc.’s SEC filings for informational purposes only. It does not constitute investment advice. Investors are urged to review the full filings and consult with a financial advisor before making investment decisions. Stock values are subject to market risk, and past performance is not indicative of future results.
